Breast Cancer: 1,219 Real Stories

1,219 stories match breast cancer. 974 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

ER-positive breast cancer: mastectomy after hormone therapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: Breast cancer was ER+ and HER2-low/negative. PR changed from positive on biopsy to negative on final pathology; HNA-1 antibody found for neutropenia.

Stage IIA ER-positive invasive ductal breast cancer had no recurrence 3 years after endocrine therapy and total mastectomy with sentinel lymph node biopsy; autoimmune neutropenia was monitored rather than directly treated.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed Central
OutcomeCare Ongoing
Kristie, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer Alliance
OutcomeSurvivorship / Completed Treatment
Krista, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Krista's Patient Story

Patient Info: Krista Brown, Female

Biomarkers: Pathogenic ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1/100

As of August 2024, Krista had completed mastectomy/reconstruction surgery and was continuing adjuvant tamoxifen with low reported recurrence risk.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Triple-Negative Breast Cancer in a Family With a Rare MT1E Variant

Patient Info: Anonymized, female, 50s

Biomarkers: Triple-negative; BRCA1/2 no pathogenic variants; MT1E c. variant identified in this family

A 56-year-old woman with a strong family history of breast cancer was treated surgically for triple-negative breast cancer while genetic testing identified a rare MT1E variant in the family.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Triple-Negative Pleomorphic Lobular Breast Cancer in a BRCA1 Carrier

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative, BRCA1 pathogenic mutation

Surgery after neoadjuvant treatment showed a complete pathologic response with no cancer in the 2 sampled sentinel lymph nodes.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

HER2-Positive Breast Cancer That Spread to the Cervix

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; ER and PR less than 1% in the left breast tumor

Metastatic Site: cervix, esophagus, mediastinal lymph nodes

Cervical metastasis showed a local complete response after brachytherapy, but systemic disease later progressed to the esophagus. She died after 4 months of nutritional support and palliative treatment.

PubMed Central
OutcomeIn Memory
Erica, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

Stage 0 DCIS breast cancer: disease-free after treatment

Patient Info: Erica, Female | Stage 0

Biomarkers: BRCA-negative

As of August 2024, Erica described herself as cancer-free after Stage 0 DCIS treated with double mastectomy and reconstruction, with peace of mind about recurrence risk.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage 3 infiltrating ductal carcinoma treated with radical mastectomy

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Breast cancer was ER/PR positive, HER2 negative

The patient recovered fully after right radical mastectomy and complete axillary dissection for Stage III male breast infiltrating ductal carcinoma; adjuvant therapy and recurrence follow-up were not reported in the extracted case text.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 invasive ductal carcinoma: metastatic disease with bone involvement managed successfully

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER <1%; PR 0%; HER2 score 3+; Ki-67 60%

Metastatic Site: bone (12th thoracic vertebra/T12)

Stage IV HER2-positive breast cancer had improved T12 bone metastasis, major breast-tumor regression on trastuzumab deruxtecan, and pathologic complete response in the breast after mastectomy; durable systemic disease status was not reported.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer history with painful implant capsule: no recurrence or BIA-ALCL found

Patient Info: Anonymized, Female, 40s

Biomarkers: Implant/capsule pathology showed necrotic tissue only; no tumor cells, CD30 signal, bacteria

The painful implant/capsule episode did not show breast cancer recurrence or BIA-ALCL on pathology; symptoms and cancer concern improved after implant removal, while oral flumatinib maintenance for acute B-lymphoblastic leukemia continued.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare acinic cell breast cancer treated with mastectomy

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative; pMMR/MSS; Ki-67 very high. TP53 and several other mutations reported; no gene fusion/rearrangement found.

Alive for 43 months with no metastasis or recurrence after surgery, 8 cycles of epirubicin/cyclophosphamide, and radiotherapy for breast acinic cell carcinoma with high-grade solid transformation.

PubMed Central
OutcomeCancer-Free / NED
Jessica, who was diagnosed with Stage I Invasive Lobular CarcinomaBreast Cancer

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed Central
OutcomeCancer-Free / NED
Samantha, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer; specific receptor details not reported

Metastatic Site: bone: rib, spine, pelvis

As of July 2024, Samantha was living with Stage IV hormone-positive breast cancer with bone metastases. Current treatment was working in most areas, but a breast tumor continued to grow and was surgically removed; ongoing treatment and 3-month scans were reported.

YouTube — The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed Central
OutcomeLiving With Cancer
Kelsey, who was diagnosed with Stage II Breast CancerBreast Cancer

Finding A Lump To BREAST CANCER!

Patient Info: Kelsey Harrison, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of July 2024, Kelsey had completed chemotherapy, double mastectomy with axillary lymph-node removal, and radiation, and was continuing tamoxifen plus Lupron ovarian suppression with additional planned systemic therapy.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II Breast Cancer Treatment Complicated by Scleroderma-Like Skin Changes

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER low-positive; PR-negative; HER2-negative

Her cancer remained stable during combination treatment. After morphea-like skin changes developed during therapy, treatment was modified and the skin condition improved 6 months after docetaxel was stopped.

PubMed Central
OutcomeCare Ongoing